Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450474 | 1.00 | ALDH1A1 (0.39) | ALDH1A1PRKDCARPDE10AKCNA3 | |
| SCHEMBL5655784 | 0.89 | KCNA3 (0.38) | ALDH1A1KCNA3 | |
| SCHEMBL8457618 | 0.79 | HRH4 (0.40) | PDE10ATSHROPRM1OPRD1OPRK1 | |
| SCHEMBL8961761 | 0.76 | MAPT (0.31) | SMN1; SMN2 | |
| SCHEMBL365122 | 0.75 | AR (0.43) | ALDH1A1PRKDCARPDE10ANOTUM | |
| SCHEMBL359662 | 0.75 | AR (0.40) | ALDH1A1ARPDE10ANOTUM | |
| SCHEMBL28986641 | 0.75 | MAP4K4 (0.39) | PDE10APOLB | |
| SCHEMBL2067477 | 0.75 | PDE10A (0.39) | ALDH1A1PRKDCARPDE10A | |
| SCHEMBL27706320 | 0.74 | CYP2D6 (0.47) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5423827 | 0.74 | KMT2A (0.50) | ALDH1A1TSHRPOLBHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | claimed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | claimed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | claimed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | claimed |
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | ALDH1A1 1393/4885PRKDC 137/4885AR 250/4885 |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | ALDH1A1 1393/4885PRKDC 137/4885AR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.